The role of dopamine agonists in early Parkinson's disease

Neurology

Volumn 49, Issue 1 SUPPL., 1997, Pages

  Watts, Ray L ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOMORPHINE; BROMOCRIPTINE; CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; ERGOT DERIVATIVE; LEVODOPA; LISURIDE; PERGOLIDE; PRAMIPEXOLE; ROPINIROLE;

ARTICLE; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SCREENING; DRUG TOLERABILITY; DYSKINESIA; HUMAN; MOTOR DYSFUNCTION; NEUROPROTECTION; PARKINSON DISEASE; PRIORITY JOURNAL;

EID: 0030737674     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.49.1_suppl_1.s34     Document Type: Article

References (87)

1. Olanow CW, Fahn S, Muenter M, et al. A multicenter double-blind placebo controlled trial of pergolide as an adjunct to Sinemet in Parkinson's disease. Mov Disord 1994;9:40-47.
2. Mouradian MM, Juncos JL, Fabbrini G, Chase TN. Motor fluctuations in Parkinson's disease: pathogenetic and therapeutic studies. Ann Neurol 1987;22:475-479.
3. Quality Standards Committee. Practice parameters: initial therapy of Parkinson's disease (summary statement). Report of the quality standards subcommittee of the American Academy of Neurology. Neurology 1993;43:1296-1297.
4. Juncos JL. Levodopa: pharmacology, pharmacokinetics, and pharmacodynamics. Neurol Clin 1992;10:487-505.
5. Fahn S. Adverse effects of levodopa in Parkinson's disease. Handbook Exp Pharmacol 1989;88:385-409.
6. Chase TN, Mouradian MM, Engber TM. Motor response complications and the function of striatal efferent systems. Neurology 1993;43(Suppl 6):S23-S26.
7. Fahn S. Controversies in the therapy of Parkinson's disease. Adv Neurol 1996;69:477-484.
8. de Jong GJ, Meerwaldt JD, Schmitz PI. Factors that influence the occurrence of response variations in Parkinson's disease. Ann Neurol 1987;22:4-7.
9. Fahn S. Adverse effects of levodopa. In: Olanow CW, Lieberman AN, eds. The Scientific Basis for the Treatment of Parkinson's Disease. Carnforth UK: Parthenon Publishing Group, 1992:89-112.
10. Kostic V, Przedborski S, Flaster E, Sternic N. Early development of levodopa-induced dyskinesias and response fluctuations in young-onset Parkinson's disease. Neurology 1991;41: 202-205.
11. Jenner P. The rationale for the use of dopamine agonists in Parkinson's disease. Neurology 1995;45(Suppl 3):S6-S12.
12. Fabbrini G, Mouradian MM, Juncos JL, Schlegel J, Mohr E, Chase TN. Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, part I. Ann Neurol 1988;24: 366-371.
13. Olanow CW. Attempts to obtain neuroprotection in Parkinson's disease. Neurology 1997;49(Suppl 1):S26-S33.
14. Olanow CW. An introduction to the free radical hypothesis in Parkinson's disease. Ann Neurol 1992;32:2-9.
15. Olanow CW. A rationale for dopamine agonists as primary therapy for Parkinson's disease. Can J Neurol Sci 1992;19: 108-112.
16. Goetz GG, Diederich NJ. Dopaminergic agonists for the treatment of Parkinson's disease. Neurol Clin 1992;10:527-540.
17. Montastruc JL, Rascol O, Senard JM. Current status of dopamine agonists in Parkinson's disease management. Drugs 1993;46:384-393.
18. Rabey JM. Second generation of dopamine agonists: pros and cons. J Neural Transm Suppl 1995;45:213-224.
19. Uitti RJ, Ahlskog JE. Comparative review of dopamine receptor agonists in Parkinson's disease. CNS Drugs 1996;5:369-387.
20. Rinne UK. Early combination of bromocriptine and levodopa in the treatment of Parkinson's disease: a 5-year follow-up. Neurology 1987;37:826-828.
21. Standaert DG, Stern MB. Update on the management of Parkinson's disease. Med Clin North Am 1993;77:169-181.
22. Tulloch IF. Pharmacologic profile of ropinirole: a nonergoline dopamine agonist. Neurology 1997;49(Suppl 1):S58-S61.
23. De Keyser J, De Backer JP, Wilczak N, Herroelen L. Dopamine agonists used in the treatment of Parkinson's disease and their selectivity for the D1, D2, and D3 dopamine receptors in human striatum. Prog Neuropsychopharmacol Biol Psychiatry 1995;19:1147-1154.
24. Cedarbaum JM, Schleifer LS. Drugs for Parkinson's disease, spasticity, and acute muscle spasms. In: Gilman AG, Rall TW, Nies AS, Taylor P, eds. Goodman and Gilman's the pharmacological basis of therapeutics, 8th ed. New York: McGraw-Hill, 1993:463-484.
25. Data on file. Pharmacia & Upjohn, Kalamazoo, MI, 1996.
26. Dostinex (cabergoline) prescribing information, Pharmacia & Upjohn, Kalamazoo, MI, 1996.
27. Physicians' Desk Reference. Montvale, NJ: Medical Economics, 1996:575-978, 2281-2284.
28. Eden RJ, Costall B, Domeney AM, et al. Preclinical pharmacology of ropinirole (SK&F 101468-A) a novel dopamine D2 agonist. Pharmacol Biochem Behav 1991;38:147-154.
29. Mierau J. Pramipexole: a dopamine-receptor agonist for treatment of Parkinson's disease. Clin Neuropharmacol 1995; 18(Suppl 1):S195-S206.
30. Hely MA, Morris JGL, Reid WGJ, et al. The Sydney multicentre study of Parkinson's disease: a report on the first 3 years. J Neurol Neurosurg Psychiatry 1994;57:324-328.
31. Lieberman A, Imke S, Muenter M, et al. Multicenter study of cabergoline, a long-acting dopamine receptor agonist, in Parkinson's disease patients with fluctuating responses to levodopa/carbidopa. Neurology 1993;43:1981-1984.
32. Dupont E, Illum F, Olivarius B. Bromocriptine and erythromelalgia-like eruptions [letter]. Neurology 1983;33: 670.
33. Calne DB, Plotkin C, Williams AC, Nutt JG, Neophytides A, Teychenne PF. Long-term treatment of parkinsonism with bromocriptine. Lancet 1978;1:735-738.
34. Eisler T, Hall RP, Kalavar KA, Calne DB. Erythromelalgia-like eruption in parkinsonian patients treated with bromocriptine. Neurology 1981;31:1368-1370.
35. Hely MA, Morris JG, Lawrence S, Jeremy R, Genge S. Retroperitoneal fibrosis, skin, and pleuropulmonary changes associated with bromocriptine therapy [letter]. Aust N Z J Med 1991;21:82-84.
36. Bowler JV, Ormerod IE, Legg NJ. Retroperitoneal fibrosis and bromocriptine [letter]. Lancet 1986;2:466.
37. McElvaney NG, Wilcox PG, Churg A, Fleetham JA. Pleuropulmonary disease during bromocriptine treatment of Parkinson's disease. Arch Intern Med 1988;148:2231-2236.
38. Todman DH, Oliver WA, Edwards RL. Pleuropulmonary fibrosis due to bromocriptine treatment for Parkinson's disease. Clin Exp Neurol 1990;27:79-82.
39. Ward CD, Thompson J, Humby MD. Pleuropulmonary and retroperitoneal fibrosis associated with bromocriptine treatment [letter]. J Neurol Neurosurg Psychiatry 1987;50:1706-1707.
40. Wiggins J, Skinner C. Bromocriptine-induced pleuropulmonary fibrosis. Thorax 1986;41:328-330.
41. Kains JP, Hardy JC, Chevalier C, Collier A. Retroperitoneal fibrosis in two patients with Parkinson's disease treated with bromocriptine. Acta Clin Belg 1990;45:306-310.
42. Murphy F, Pickard RS. Bromocriptine-associated retroperitoneal fibrosis presenting with testicular retraction. Br J Urol 1989;64:318-319.
43. Sanchez Chapado M, Angulo Cuesta J, Guil CM, Jimenez FJ, Lopez Alverez YJ. Retroperitoneal fibrosis secondary to treatment with L-dopa analogues for Parkinson's disease [Spanish]. Arch Esp Urol 1995;48:979-983.
44. Jimenez-Jimenez FJ, Lopez-Alvarez J, Sanchez-Chapado M, et al. Retroperitoneal fibrosis in a patient with Parkinson's disease treated with pergolide. Clin Neuropharmacol 1995;18: 277-279.
45. Frans E, Dom R, Demedts M. Pleuropulmonary changes during treatment of Parkinson's disease with a long-acting ergot derivative, cabergoline. Eur Respir J 1992;5:263-265.
46. Data on file. SmithKline Beecham Pharmaceuticals, Philadelphia, PA, 1996.
47. Ahlskog JE, Muenter MD. Treatment of Parkinson's disease with pergolide: a double-blind study. Mayo Clin Proc 1988;63: 969-978.
48. Brooks DJ, Torjanski N, Burn DJ. Ropinirole in the symptomatic treatment of Parkinson's disease. J Neural Transm Suppl 1995;45:231-238.
49. 2 agonist, ropinirole, as adjunct therapy [abstract]. Neurology 1991; 41(Suppl 1):A399.
50. Diamond SG, Markham CH, Treciokas LJ. Double-blind trial of pergolide for Parkinson's disease. Neurology 1985;35:291-295.
51. Kreider M, Knox S. A multicenter double-blind study of ropinirole as an adjunct to L-dopa in Parkinson's disease [abstract]. Neurology 1996;46(Suppl):A475.
52. Lieberman AN, Goldstein M. Bromocriptine in Parkinson's disease. Pharmacol Rev 1985;37:217-227.
53. Rascol O, Lees AJ, Senard JM, Pirtosek D, Murray G. Ropinirole: a double-blind placebo-controlled study of efficacy and safety as adjunct therapy in Parkinsonian patients with on-off fluctuations. Neurology 1993;43(Suppl 2):A348.
54. Rinne UK. Dopamine agonists in the treatment of Parkinson's disease. In: Rinne UK, Yanagisawa N, eds. Controversies in Treatment of Parkinson's Disease. PMSI: Tokyo, Japan, 1992: 49-60.
55. Montastruc JL, Rascol O, Senard JM, Rascol A. A randomized controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow-up. J Neurol Neurosurg Psychiatry 1994;57:1034-1038.
56. Rascol A, Guiraud-Chaumeil B, Montrastruc JL, Clanet M. Long-term treatment of Parkinson's disease with bromocriptine. J Neurol Neurosurg Psychiatry 1979;42:143-150.
57. Rinne UK. Combined bromocriptine-levodopa therapy early in Parkinson's disease. Neurology 1985;35:1196-1198.
58. Bergamasco B, Benna P, Scarzella L. Long-term bromocriptine treatment of de novo patients with Parkinson's disease: a seven-year follow-up. Acta Neurol Scand 1990;81:383-387.
59. The Bromocriptine Multicentre Trial Group. Bromocriptine as initial therapy in elderly parkinsonian patients. Age Ageing 1990;19:62-67.
60. Montastruc JL, Rascol O, Rascol A. A randomized controlled study of bromocriptine versus levodopa in previously untreated parkinsonian patients: a 3 year follow-up. J Neurol Neurosurg Psychiatry 1989;52:773-775.
61. Parkinson's Disease Research Group in the United Kingdom. Comparisons of therapeutic effects of levodopa, levodopa and selegiline, and bromocriptine in patients with early, mild Parkinson's disease: three year interim report. BMJ 1993;307: 469-472.
62. Nakanishi T, Iwata M, Goto I, et al. Nationwide collaborative study on the long-term effects of bromocriptine in the treatment of parkinsonian patients. Eur Neurol 1992;32(Suppl 1): 9-22.
63. Wolters EC, Tissingh G, Bergmans PLM, Kuiper MA. Dopamine agonists in Parkinson's disease. Neurology 1995; 45(Suppl 3):S28-S34.
64. Langtry HD, Clissold SP. Pergolide: a review of its pharmacological properties and therapeutic potential in Parkinson's disease. Drugs 1990;39:491-506.
65. Korczyn A. A double-blind study comparing ropinirole and bromocriptine in patients with early Parkinson's disease [abstract]. Neurology 1996;46(Suppl):A159.
66. Rascol O. A double blind L-dopa controlled study of ropinirole patients with early Parkinson's disease [abstract]. Neurology 1996;46(Suppl):A139.
67. Wheadon DE, Wilson-Lynch K, Gardiner D, Kreider MS. Ropinirole, a non-ergoline D2 agonist, is effective in early parkinsonian patients not treated with L-dopa [abstract]. Neurology 1996;46(Suppl):A159.
68. Hubble JP, Koller WC, Cutler NR, et al. Pramipexole in patients with early Parkinson's disease. Clin Neuropharmacol 1995;18:338-347.
69. Shannon KM. New alternatives for the management of early Parkinson's disease [abstract]. Mov Disord 1996;11(Suppl 1): A266.
70. Rinne UK. Treatment of "de novo" parkinsonian patients: the role of Cabergoline. Fourth International Congress of Movement Disorders, 16-21 June 1996, Vienna, Austria.
71. Grimes JD, Hassan MN. Evidence to support the simultaneous initiation of dopamine agonist and levodopa therapy in the management of patients with Parkinson's disease [abstract]. Arch Neurol 1988;45:206.
72. Olsson JE, European Multicentric Trial Group. Bromocriptine and levodopa in early combination in Parkinson's disease: first results of the Collaborative European Multicentric Trial. Adv Neurol 1990;53:421-423.
73. Factor SA, Weiner WJ. Early combination therapy with bromocriptine and levodopa in Parkinson's disease. Mov Disord 1993;8:257-262.
74. Weiner WJ, Factor SA, Sanchez-Ramos JR, et al. Early combination therapy (bromocriptine and levodopa) does not prevent motor fluctuations in Parkinson's disease. Neurology 1993;43:21-27.
75. Calne DB. Initiating treatment for idiopathic parkinsonism. Neurology 1994;44(Suppl 6):S19-S22.
76. Calne DB. Treatment of Parkinson's disease. N Engl J Med 1993;329:1021-1027.
77. Koller W, Silver D, Lieberman A. An algorithm for managing Parkinson's disease. Neurology 1994;44(Suppl 1):S1-S52.
78. Montamat SC, Cusak BJ, Vestal RE. Management of drug therapy in the elderly. N Engl J Med 1989;321:303-309.
79. Stacy M, Brownlee HJ. Treatment options for early Parkinson's disease. Am Fam Physician 1996;53:1281-1287.
80. Mayeux R, Chen J, Mirabello E, et al. An estimate of the incidence of dementia in idiopathic Parkinson's disease. Neurology 1990;46:1513-1517.
81. Jankovic J, McDermott M, Carter J, et al. Variable expression of Parkinson's disease: a baseline analysis of the DATATOP cohort. Neurology 1990;40:1529-1534.
82. Dooneief G, Mirabello E, Bell K, et al. An estimate of the incidence of depression in idiopathic Parkinson's disease. Arch Neurol 1992;49:305-307.
83. Biggins CA, Boyd JL, Harrop FM, et al. A controlled, longitudinal study of dementia in Parkinson's disease. J Neurol Neurosurg Psychiatary 1992;55:566-571.
84. Saint-Cyr JA, Taylor AE, Lang AE. Neuropsychological and psychiatric side effects in the treatment of Parkinson's disease. Neurology 1993;43(Suppl 6):S47-S52.
85. Fahn S, Bressman SB. Should levodopa therapy for parkinsonism be started early or late? Evidence against early treatment. Can J Neurol Sci 1984;11(Suppl 1):200-205.
86. Quinn N, Critchley P, Marsden CD. Young onset Parkinson's disease. Mov Disord 1987;2:73-91.
87. Goetz CG. Dopaminergic agonists in the treatment of Parkinson's disease. Neurology 1990;40(Suppl 3):S50-S54.